Evidence map›Paper›PMID 40045303›Full record

ArticleSubstance abuse treatment, prevention, and policy2025

Alcohol use disorder among people diagnosed with tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence.

Josephine Bayigga, Ilona Kakai, Eva Agnes Laker Odongpiny, Ahmed Ddungu, Lynn Semakula, Martha Nansereko, Christine Sekaggya Wiltshire, Turyahabwe Stavia, Stella Zawedde-Muyanja

Abstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Tuberculosis: An Ongoing Global Threat.Advances in experimental medicine and biology · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Josephine BayiggaThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Ilona KakaiThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Eva Agnes Laker OdongpinyThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Ahmed DdunguThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Lynn SemakulaThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Martha NanserekoThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Christine Sekaggya WiltshireThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda.
Turyahabwe StaviaUganda Tuberculosis and Leprosy Program, Uganda Ministry of Health, Kampala, Uganda.
Stella Zawedde-MuyanjaThe Infectious Diseases Institute, College of Health Sciences, Makerere University Kampala, Kampala, Uganda. szawedde@idi.co.ug.

Funding

HIV Co-infections in Uganda: TB, Cryptococcus, and Viral Hepatitis.D43TW009771 · FIC · JOHNS HOPKINS UNIVERSITY · PI CASTELNUOVO, BARBARA, KAMBUGU, ANDREW DDUNGU · 2014 to 2023
$3.3M
FIC NIH HHS D43 TW009771WHO STOP TB Partnership Wave 7
6 · The paper itself

Abstract

backgroundHeavy consumption of alcohol increases the risk of developing active tuberculosis (TB), contributes to delayed diagnosis and affects adherence to treatment. Within a large urban case-finding project, we aimed to determine the prevalence of and factors associated with alcohol use disorder (AUD) and to understand the challenges that people with AUD face while seeking for TB services and adhering to TB treatment.

methodsWe carried out an explanatory sequential study in two large urban districts in Uganda. We collected quantitative data on the prevalence of alcohol use disorder using the Cut, Annoyed, Guilty, Eye opener (CAGE) tool. We used a Poisson regression model with robust variance to examine factors associated with AUD. Both the crude and adjusted prevalence risk ratios with 95% confidence intervals were presented. We then conducted two focus group discussions with persons diagnosed with both TB and AUD. Focus group discussions (FGDs) were transcribed, data were analysed inductively and coded into themes using NVIVO version 12 software.

resultsOut of 325 people with TB people interviewed, 62 (18.7% 95% confidence interval [CI] 18-31%) screened positive for AUD. Majority 82.3% (51/62) were male. Being male aPR 2.32 (95% CI 1.19, 4.49) and living in an urban area aOR 1.79 (95% CI: 1.10, 2.92) were significantly associated with a positive screen. Among people who screened positive for AUD, there was a tendency towards suboptimal TB treatment outcomes, although this did not reach significance aPR 1.65 (95% CI: 0.95, 2.85). Fourteen people (eight male and six female) who screened positive for AUD attended two FGDs. These respondents often did not disclose alcohol use during TB treatment and missed clinic refill appointments due to lack of transport fares to the clinic.

conclusionA significant proportion of people with TB screened positive for AUD but did not disclose alcohol use to their healthcare workers. These patients experienced several challenges while on TB treatment. Therefore, TB care programs need to design interventions that actively assess for AUD and in order to address related challenges.

Indexed as

AlcoholismTreatment Adherence and ComplianceTuberculosisAdolescentAdultFemaleFocus GroupsHumansMaleMiddle AgedPrevalenceRisk FactorsUgandaUrban PopulationYoung AdultAlcohol use disorderExperiencesTreatment outcomesTuberculosisUganda

Identifiers

PMID40045303
PMCPMC11881283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.